Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient
Open accessThe DOI matches its Crossref record; 166 of the 167 references it cites were found in a registry or an index.
Abstract
Major depressive disorder is an often chronic and recurring illness. Left untreated, major depressive disorder may result in progressive alterations in brain morphometry and circuit function. Recent findings, however, suggest that pharmacotherapy may halt and possibly reverse those effects. These findings, together with evidence that a delay in treatment is associated with poorer clinical outcomes, underscore the urgency of rapidly treating depression to full recovery. Early optimized treatment, using measurement-based care and customizing treatment to the individual patient, may afford the best possible outcomes for each patient. The aim of this article is to present recommendations for using a patient-centered approach to rapidly provide optimal pharmacological treatment to patients with major depressive disorder. Offering major depressive disorder treatment determined by individual patient characteristics (e.g., predominant symptoms, medical history, comorbidities), patient preferences and expectations, and, critically, their own definition of wellness provides the best opportunity for full functional recovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This dysfunction contributes to compulsive actions by reinforcing rigid, maladaptive response patterns that resist modification, thereby reducing cognitive flexibility, particularly in contexts involving task shifts, feedback adaptation, or updating based on new information (13, 21, 172).”
From Neural mechanisms underlying cognitive inflexibility in obsessive-compulsive disorder: a review (2026) · cites this paper as [172]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 1×
“In addition to mood symptoms, individuals with MDD experience impairments in physical, occupational, and social functioning (Kessler et al., 2003; American Psychiatric Association, 2013).”
BackgroundOsterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
The PHQ-9: A New Depression Diagnostic and Severity Measure
Kroenke, K., & Spitzer, R. L. (2002) · Psychiatric Annals · doi:10.3928/0048-5713-20020901-06 · Cited by 5,898 · cited 11×
“Guideline-based validated instruments such as the PHQ-9 or Quick Inventory of Depressive Symptomatology, in contrast, are fast, easy, and self-administered (Kroenke and Spitzer, 2002; Rush et al., 2006a; Thase, 2014b).”
BackgroundMethodInfluentialRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
KESSLER, R. C., ADLER, L., AMES, M., DEMLER, O., FARAONE, S., HIRIPI, E., HOWES, M. J., JIN, R., SECNIK, K., SPENCER, T., et al. (2005) · Psychological Medicine · doi:10.1017/s0033291704002892 · Cited by 3,452 · cited 2×
“, 2012), the authors recommend assessing for ADHD using the Adult ADHD Self-Report Scale (Kessler et al., 2005) in patients with treatment-resistant depression.”
MethodAssessment of social adjustment by patient self report.
Weissman, M. M. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770090101010 · Cited by 1,782 · cited 1×
“…7 scored on a 5-point, Likert scale Lam et al., 2009) Social Adjustment Scale, Self-Report Version 48 items in 6 domains, each rated on a 5-point, Likert scale Weissman and Bothwell, 1976 Social and Occupational Functioning Assessment Scale Single scale, scored 0–100 Rybarczyk, 2011 EuroQoL-5D…”
MethodCipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 2×
“…neurogenesis in the hippocampus (Boldrini et al., 2012, 2013; Duric et al., 2013; Furtado et al., 2013; Phillips et al., 2015), and preclinical work (Duman and Aghajanian, 2012; Licznerski and Duman, 2013; Bortolotto et al., 2014) supports the hypothesis that depression may disrupt neural…”
BackgroundResultHippocampal volume and depression: a meta-analysis of MRI studies
Videbech, P., & Ravnkilde, B. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.1957 · Cited by 1,590 · cited 2×
“Untreated MDD is associated with damage to the brain, evident as loss of volume in various brain areas, including the hippocampus (Videbech and Ravnkilde, 2004; McKinnon et al., 2009; MacQueen and Frodl, 2011).”
BackgroundSheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Screening for Depression in Adults: US Preventive Services Task Force Recommendation Statement
Siu, A. L., and the US Preventive Services Task Force (USPSTF), Bibbins-Domingo, K., Grossman, D. C., Baumann, L. C., Davidson, K. W., Ebell, M., García, F. A. R., Gillman, M., Herzstein, J., et al. (2016) · JAMA · doi:10.1001/jama.2015.18392 · Cited by 1,407
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Self-citationUntreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180 · cited 1×
“Hippocampal volume loss is more severe in patients with a longer duration of untreated depression (Sheline et al., 2003; McKinnon et al., 2009; MacQueen and Frodl, 2011).”
BackgroundHandbook of Psychiatric Measures
SALZMAN, C. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1343 · Cited by 1,174
for the ENIGMA-Major Depressive Disorder Working Group, Schmaal, L., Veltman, D. J., van Erp, T. G. M., Sämann, P. G., Frodl, T., Jahanshad, N., Loehrer, E., Tiemeier, H., Hofman, A., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.69 · Cited by 1,172
Self-citationAnderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908 · cited 1×
“…Association for Psychopharmacology, NICE, and CANMAT recommendations define MDD severity according to DSM criteria only (Work Group on Major Depressive Disorder, 2010; Anderson et al., 2008; National Instutute for Health and Clinical Excellence, 2009; Bauer et al., 2013; MacQueen et al., 2016).”
BackgroundMcKinnon, M. C., Yucel, K., Nazarov, A., & MacQueen, G. M. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0905 · Cited by 742
Self-citationThe STAR*D project results: A comprehensive review of findings
Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0061-3 · Cited by 727 · cited 1×
“…such as age at the onset of depression, time since the onset of depression, duration of the current episode, and the number of previous episodes may also predict treatment outcome (Warden et al., 2007; Howland et al., 2008; Fava et al., 2009; Seemuller et al., 2010; Joel et al., 2014).”
BackgroundMacQueen, G., & Frodl, T. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.80 · Cited by 665 · cited 4×
“Hippocampal volume loss is more severe in patients with a longer duration of untreated depression (Sheline et al., 2003; McKinnon et al., 2009; MacQueen and Frodl, 2011).”
BackgroundInfluentialSelf-citationBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632 · cited 1×
“…Association for Psychopharmacology, NICE, and CANMAT recommendations define MDD severity according to DSM criteria only (Work Group on Major Depressive Disorder, 2010; Anderson et al., 2008; National Instutute for Health and Clinical Excellence, 2009; Bauer et al., 2013; MacQueen et al., 2016).”
BackgroundAntidepressants and Body Weight: A Comprehensive Review and Meta-Analysis
Serretti, A., & Mandelli, L. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05346blu · Cited by 621 · cited 2×
“Although adverse events are associated with all drugs, specific antidepressants are associated with higher rates of particularly troublesome side effects, such as weight gain and sexual dysfunction (Ashton et al., 2005; Serretti and Chiesa, 2009; Serretti and Mandelli, 2010; Clayton et al., 2014).”
BackgroundTreatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis
Serretti, A., & Chiesa, A. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a5233f · Cited by 583 · cited 2×
“Although adverse events are associated with all drugs, specific antidepressants are associated with higher rates of particularly troublesome side effects, such as weight gain and sexual dysfunction (Ashton et al., 2005; Serretti and Chiesa, 2009; Serretti and Mandelli, 2010; Clayton et al., 2014).”
BackgroundParikh, S. V., Quilty, L. C., Ravitz, P., Rosenbluth, M., Pavlova, B., Grigoriadis, S., Velyvis, V., Kennedy, S. H., Lam, R. W., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659418 · Cited by 562
Self-citationMoylan, S., Maes, M., Wray, N. R., & Berk, M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.33 · Cited by 529 · cited 1×
“Failure to rapidly and effectively treat major depression may have lasting effects on patients’ brain structure and function, which may worsen progressively with successive depressive episodes (Moylan et al., 2013).”
BackgroundDiagnostic and Statistical Manual of Mental Disorders (DSM)
Matsuno, E. (2024) · The Sage Encyclopedia of LGBTQ+ STUDIES · doi:10.4135/9781071891414.n132 · Cited by 510
Sheehan, K. H., & Sheehan, D. V. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2b4d6 · Cited by 467 · cited 3×
“Improvement in function and quality of life often lags behind symptom remission in patients with MDD (Bech, 2005; Sheehan and Sheehan, 2008; IsHak et al., 2011).”
BackgroundMethodHow Should Remission From Depression Be Defined? The Depressed Patient’s Perspective
Zimmerman, M., McGlinchey, J. B., Posternak, M. A., Friedman, M., Attiullah, N., & Boerescu, D. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.148 · Cited by 431 · cited 1×
“It is essential to consider that a patient’s concept of wellness may differ substantially from that of the treating physician (Zimmerman et al., 2006; McIntyre et al., 2015), and ultimately, it is the patient’s concept that is the most important treatment goal.”
BackgroundUher, R., Perlis, R. H., Henigsberg, N., Zobel, A., Rietschel, M., Mors, O., Hauser, J., Dernovsek, M. Z., Souery, D., Bajs, M., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291711001905 · Cited by 420 · cited 2×
“with differences in efficacy or tolerability for specific drugs or classes (Uher et al., 2012; Kennedy et al., 2016).”
BackgroundContinuity of antidepressant treatment for adults with depression in the United States
Olfson, M., Marcus, S. C., Tedeschi, M., & Wan, G. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.101 · Cited by 392
Rush, A. J., Bernstein, I. H., Trivedi, M. H., Carmody, T. J., Wisniewski, S., Mundt, J. C., Shores-Wilson, K., Biggs, M. M., Woo, A., Nierenberg, A. A., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.022 · Cited by 385
Boldrini, M., Santiago, A. N., Hen, R., Dwork, A. J., Rosoklija, G. B., Tamir, H., Arango, V., & John Mann, J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.5 · Cited by 361
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K., Lux, L., Van Noord, M., Mager, U., Thieda, P., Gaynes, B. N., Wilkins, T., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-11-201112060-00009 · Cited by 355 · cited 1×
“While antidepressants may be similar in efficacy overall (Work Group on Major Depressive Disorder, 2010; Gartlehner et al., 2011; Schueler et al., 2011), published literature suggests there may be potential benefits of some drugs in individuals with specific symptoms or comorbid conditions…”
BackgroundBoldrini, M., Hen, R., Underwood, M. D., Rosoklija, G. B., Dwork, A. J., Mann, J. J., & Arango, V. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.024 · Cited by 348
Major Depressive Disorder Treatment Guidelines in America and Europe
Davidson, J. R. T. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.9058se1c.04gry · Cited by 344 · cited 6×
“The DSM-5 and ICD-10 criteria for severity include both number of symptoms and degree of impairment or disability (Davidson, 2010) The American Psychiatric Association, the British Association for Psychopharmacology, NICE, and CANMAT recommendations define MDD severity according to DSM criteria…”
BackgroundInfluentialSzegedi, A., Jansen, W. T., van Willigenburg, A. P. P., van der Meulen, E., Stassen, H. H., & Thase, M. E. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03780 · Cited by 341 · cited 1×
“Baseline and weekly assessments of both depressive symptoms and functioning are therefore recommended (Szegedi et al., 2009; Lam et al., 2011).”
BackgroundRavindran, A. V., Balneaves, L. G., Faulkner, G., Ortiz, A., McIntosh, D., Morehouse, R. L., Ravindran, L., Yatham, L. N., Kennedy, S. H., Lam, R. W., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716660290 · Cited by 337
Self-citationQuality of life: The ultimate outcome measure of interventions in major depressive disorder
IsHak, W. W., Greenberg, J. M., Balayan, K., Kapitanski, N., Jeffrey, J., Fathy, H., Fakhry, H., & Rapaport, M. H. (2011) · Harvard Review of Psychiatry · doi:10.3109/10673229.2011.614099 · Cited by 313 · cited 2×
“Improvement in function and quality of life often lags behind symptom remission in patients with MDD (Bech, 2005; Sheehan and Sheehan, 2008; IsHak et al., 2011).”
BackgroundContinuity of Antidepressant Treatment for Adults With Depression in the United States
Ballenger, J. C. (2007) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70480-8 · Cited by 313
Defining and Assessing Adherence to Oral Antipsychotics: A Review of the Literature
Velligan, D. I., Lam, Y.-W. F., Glahn, D. C., Barrett, J. A., Maples, N. J., Ereshefsky, L., & Miller, A. L. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj075 · Cited by 309 · cited 1×
“Tools for assisting the physician in monitoring adherence include electronic monitoring, pill counts, blister-packing medications, medication diaries, patient self-reporting, chart reviews, easy availability of prescription renewal, and pharmacy records (Osterberg and Blaschke, 2005; Velligan et al., 2006; Byerly et a…”
BackgroundMiller, I. W., Keitner, G. I., Schatzberg, A. F., Klein, D. N., Thase, M. E., Rush, A. J., Markowitz, J. C., Schlager, D. S., Kornstein, S. G., Davis, S. M., et al. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1108 · Cited by 305 · cited 1×
“previous functioning may have a slower trajectory compared with symptomatic improvement during treatment (Miller et al., 1998; Bech, 2005; Papakostas, 2009; IsHak et al., 2011).”
BackgroundDuric, V., Banasr, M., Stockmeier, C. A., Simen, A. A., Newton, S. S., Overholser, J. C., Jurjus, G. J., Dieter, L., & Duman, R. S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000016 · Cited by 304 · cited 1×
“The continued presence of depressive symptoms may promote chronic neuronal loss and suppress neurogenesis in the hippocampus (Boldrini et al., 2012, 2013; Duric et al., 2013; Furtado et al., 2013; Phillips et al., 2015), and preclinical work (Duman and Aghajanian, 2012; Licznerski and Duman, 2013; Bortolotto et al.”
BackgroundThase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0803 · Cited by 304
Clerc, G. E., Ruimy, P., & Verdeau-Paillès, J. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199409000-00001 · Cited by 298
Lam, R. W., McIntosh, D., Wang, J., Enns, M. W., Kolivakis, T., Michalak, E. E., Sareen, J., Song, W.-Y., Kennedy, S. H., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659416 · Cited by 288
Self-citationState-dependent changes in hippocampal grey matter in depression
Arnone, D., McKie, S., Elliott, R., Juhasz, G., Thomas, E. J., Downey, D., Williams, S., Deakin, J. F. W., & Anderson, I. M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.150 · Cited by 287 · cited 6×
“tions in brain morphometry and circuit dysfunction that can be observed as volume loss in the hippocampus and other areas implicated in depression (Geerlings et al., 2012; Sheline et al., 2012; Arnone et al., 2013; Huang et al., 2013; Nugent et al., 2013; Zhao et al., 2014; Schmaal et al., 2016).”
BackgroundResultInfluentialGhio, L., Gotelli, S., Marcenaro, M., Amore, M., & Natta, W. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.002 · Cited by 249 · cited 1×
“Furthermore, delaying effective treatment may reduce the likelihood of both asymptomatic remission and functional recovery, and increase the time to achieve remission (Gormley et al., 1999; Okuda et al., 2010; Bukh et al., 2013; Ghio et al., 2014).”
BackgroundMacQueen, G. M., Frey, B. N., Ismail, Z., Jaworska, N., Steiner, M., Lieshout, R. J. V., Kennedy, S. H., Lam, R. W., Milev, R. V., Parikh, S. V., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659276 · Cited by 248
Self-citationRecommendations on screening for depression in adults
Canadian Task Force on Preventive Health Care, Joffres, M., Jaramillo, A., Dickinson, J., Lewin, G., Pottie, K., Shaw, E., Gorber, S. C., & Tonelli, M. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.130403 · Cited by 247 · cited 4×
“numerous agencies do not recommend routine screening for depression in adults unless adequate resources and services are available for subsequent diagnostic assessment and management (National Institute for Health and Clinical Excellence, 2009; Joffres et al., 2013; Lam et al., 2016; Siu et al., 2016).”
BackgroundInfluentialReliability and Validity of a Brief Patient-Report Instrument for Psychiatric Outcome Evaluation
Eisen, S. V., Dill, D. L., & Grob, M. C. (1994) · Psychiatric Services · doi:10.1176/ps.45.3.242 · Cited by 241
Gartlehner, G., Gaynes, B. N., Hansen, R. A., Thieda, P., DeVeaugh-Geiss, A., Krebs, E. E., Moore, C. G., Morgan, L., & Lohr, K. N. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-10-200811180-00008 · Cited by 237
Tolerability and adherence issues in antidepressant therapy
Masand, P. S. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80220-5 · Cited by 213 · cited 3×
“…low motivation, medication cost, delayed onset of efficacy, weight gain, sexual dysfunction, failure of patients to perceive benefits of treatment, and premature discontinuation of treatment after symptoms have improved (Masand, 2003; Ashton et al., 2005; Burra et al., 2007; Fortney et al., 2011).”
BackgroundUS Preventive Services Task Force (2009) · Pediatrics · doi:10.1542/peds.2008-2381 · Cited by 207
Schmaal, L., Veltman, D. J., van Erp, T. G. M., Sämann, P. G., Frodl, T., Jahanshad, N., Loehrer, E. A., Tiemeier, H. W., Albert Hofman, D., Niessen, W. J., et al. (2015) · QUT ePrints (Queensland University of Technology) · Cited by 207
Self-citationDemyttenaere, K., Enzlin, P., Dewé, W., Boulanger, B., Bie, J. D., Troyer, W. D., & Mesters, P. (2001) · PubMed · Cited by 204
Zhao, Y.-J., Du, M.-Y., Huang, X.-Q., Lui, S., Chen, Z.-Q., Liu, J., Luo, Y., Wang, X.-L., Kemp, G. J., & Gong, Q.-Y. (2014) · Psychological Medicine · doi:10.1017/s0033291714000518 · Cited by 203 · cited 1×
“A significant reduction in hippocampal volume has been reported as early as the first depressive episode (Zhao et al., 2014), although other studies have found no volumetric differences between first episode patients and healthy controls (McKinnon et al., 2009; Schmaal et al., 2016).”
BackgroundHo, S. C., Chong, H. Y., Chaiyakunapruk, N., Tangiisuran, B., & Jacob, S. A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.12.029 · Cited by 186 · cited 1×
“Medication adherence is critical to achieving full, functional recovery and is one of the major challenges hindering optimal treatment of MDD (Kohler et al., 2012; Ho et al., 2015; Lam et al., 2016).”
BackgroundHuang, Y., Coupland, N. J., Lebel, R. M., Carter, R., Seres, P., Wilman, A. H., & Malykhin, N. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.01.005 · Cited by 179
Szegedi, A., Müller, M. J., Anghelescu, I., Klawe, C., Kohnen, R., & Benkert, O. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0410 · Cited by 174
Henkel, V., Seemüller, F., Obermeier, M., Adli, M., Bauer, M., Mundt, C., Brieger, P., Laux, G., Bender, W., Heuser, I., et al. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.10.011 · Cited by 167
Qaseem, A., Snow, V., Denberg, T. D., Forciea, M. A., & Owens, D. K. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-10-200811180-00007 · Cited by 165 · cited 1×
“Clinicians have historically used a “start low and go slow” approach to pharmacotherapy for MDD, prescribing an initial antidepressant trial for up to 6 to 8 weeks before concluding that the treatment has failed and an adjustment is warranted (Work Group on Major Depressive Disorder, 2010; Qaseem et al., 2008).”
MethodA clinically useful depression outcome scale
Zimmerman, M., Chelminski, I., McGlinchey, J. B., & Posternak, M. A. (2008) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2007.10.006 · Cited by 161
Tendolkar, I., van Beek, M., van Oostrom, I., Mulder, M., Janzing, J., Voshaar, R. O., & van Eijndhoven, P. (2013) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2013.09.004 · Cited by 161 · cited 1×
“Treatment of depression is generally associated with an increase in hippocampal volume (Schermuly et al., 2011; Huang et al., 2013; Tendolkar et al., 2013) or at least a slowing of volume loss (Elbejjani et al.”
BackgroundRemodeling of axo-spinous synapses in the pathophysiology and treatment of depression
Licznerski, P., & Duman, R. S. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.057 · Cited by 157 · cited 2×
“, 2015), and preclinical work (Duman and Aghajanian, 2012; Licznerski and Duman, 2013; Bortolotto et al., 2014) supports the hypothesis that depression may disrupt neural connections in mood-related circuits and provides preliminary evidence that treatment may ameliorate these processes.”
BackgroundResultAntidepressants and Sexual Dysfunction: Mechanisms and Clinical Implications
Clayton, A. H., Croft, H. A., & Handiwala, L. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.03.2744 · Cited by 152 · cited 1×
“Although adverse events are associated with all drugs, specific antidepressants are associated with higher rates of particularly troublesome side effects, such as weight gain and sexual dysfunction (Ashton et al., 2005; Serretti and Chiesa, 2009; Serretti and Mandelli, 2010; Clayton et al., 2014).”
BackgroundGartlehner, G., Thieda, P., Hansen, R. A., Gaynes, B. N., DeVeaugh-Geiss, A., Krebs, E. E., & Lohr, K. N. (2008) · Drug Safety · doi:10.2165/00002018-200831100-00004 · Cited by 150
Machado, M., Iskedjian, M., Ruiz, I., & Einarson, T. R. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x132415 · Cited by 144 · cited 3×
“Rates of remission are low for any given drug (approximately ≤50%) across groups of patients evaluated in antidepressant clinical trials (Thase et al., 2005; Machado et al., 2006) and may be lower among patients treated in clinical prac-”
BackgroundPsychometric properties of the WHODASII in rehabilitation patients
Pösl, M., Cieza, A., & Stucki, G. (2007) · Quality of Life Research · doi:10.1007/s11136-007-9259-4 · Cited by 144
Phillips, J. L., Batten, L. A., Tremblay, P., Aldosary, F., & Blier, P. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv037 · Cited by 144 · cited 3×
“…may promote chronic neuronal loss and suppress neurogenesis in the hippocampus (Boldrini et al., 2012, 2013; Duric et al., 2013; Furtado et al., 2013; Phillips et al., 2015), and preclinical work (Duman and Aghajanian, 2012; Licznerski and Duman, 2013; Bortolotto et al., 2014) supports the…”
BackgroundResultSelf-citationAntidepressant-related adverse effects impacting treatment compliance: Results of a patient survey
Ashton, A. K., Jamerson, B. D., Weinstein, W., & Wagoner, C. (2005) · Current Therapeutic Research · doi:10.1016/j.curtheres.2005.04.006 · Cited by 144 · cited 5×
“…low motivation, medication cost, delayed onset of efficacy, weight gain, sexual dysfunction, failure of patients to perceive benefits of treatment, and premature discontinuation of treatment after symptoms have improved (Masand, 2003; Ashton et al., 2005; Burra et al., 2007; Fortney et al., 2011).”
BackgroundInfluentialThe effect of prolonged duration of untreated depression on antidepressant treatment outcome
Bukh, J. D., Bock, C., Vinberg, M., & Kessing, L. V. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.07.008 · Cited by 140
Hippocampus atrophy and the longitudinal course of late-life depression
Taylor, W. D., McQuoid, D. R., Payne, M. E., Zannas, A. S., MacFall, J. R., & Steffens, D. C. (2014) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.11.004 · Cited by 134 · cited 4×
“More severe symptoms of depression are associated with greater hippocampal volume loss (Huang et al., 2013; Taylor et al., 2014; Elbejjani et al., 2015).”
BackgroundInfluentialByerly, M. J., Thompson, A., Carmody, T., Bugno, R., Erwin, T., Kashner, M., & Rush, A. J. (2007) · Psychiatric Services · doi:10.1176/appi.ps.58.6.844 · Cited by 134
Bond, D. J., Hadjipavlou, G., Lam, R. W., McIntyre, R. S., Beaulieu, S., Schaffer, A., & Weiss, M. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400104 · Cited by 133 · cited 1×
“Because patients with MDD have a 2-fold higher prevalence of ADHD relative to the general population and the presence and severity of comorbid ADHD can inform treatment selection for both conditions (Canadian Attention Deficit Hyperactivity Disorder Resource Alliance, 2011; Bond et al., 2012), the authors recommend as…”
MethodSelf-citationNeuroimaging-based biomarkers for treatment selection in major depressive disorder
Dunlop, B. W., & Mayberg, H. S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/bdunlop · Cited by 127 · cited 2×
“…have yet to demonstrate a positive impact on health outcomes in clinical practice; however, future research may eventually prove biomarkers to be beneficial in selecting appropriate antidepressants in specific patient populations (Dunlop and Mayberg, 2014; Leuchter et al., 2014; Thase, 2014a).”
BackgroundSheehan, D. V., Harnett-Sheehan, K., Spann, M. E., Thompson, H. F., & Prakash, A. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328341bb5f · Cited by 124
Trivedi, M. H., Morris, D. W., Wisniewski, S. R., Lesser, I., Nierenberg, A. A., Daly, E., Kurian, B. T., Gaynes, B. N., Balasubramani, G. K., & Rush, A. J. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12020250 · Cited by 121 · cited 1×
“greater improvements in function compared with patients who remitted at step 2 (Trivedi et al., 2013).”
ResultClinical effectiveness: The importance of psychosocial functioning outcomes
Lam, R. W. M., Filteau, M., & Milev, R. V. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.03.046 · Cited by 118 · cited 1×
“Baseline and weekly assessments of both depressive symptoms and functioning are therefore recommended (Szegedi et al., 2009; Lam et al., 2011).”
BackgroundSelf-citationMöller, H.-J. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970801981606 · Cited by 114 · cited 3×
“Clinical evidence supports maintenance treatment of MDD with pharmacotherapy, psychotherapy, and other non-pharmacotherapies (Moller, 2008; Glue et al., 2010; Lam et al., 2016).”
BackgroundTsai, M.-H., Lin, K.-M., Hsiao, M.-C., Shen, W. W., Lu, M.-L., Tang, H.-S., Fang, C.-K., Wu, C.-S., Lu, S.-C., Liu, S. C., et al. (2010) · Pharmacogenomics · doi:10.2217/pgs.09.168 · Cited by 114 · cited 1×
“In depressed patients administered escitalopram, CYP2D6 genotypes yielding more rapid metabolism were significantly associated with a slower time to remission, and CYP2C19 poor metabolizers had significantly higher serum escitalopram levels compared with extensive metabolizers (Tsai et al., 2010).”
BackgroundClarke, K., Mayo-Wilson, E., Kenny, J., & Pilling, S. (2015) · Clinical Psychology Review · doi:10.1016/j.cpr.2015.04.002 · Cited by 113
Thase, M. E., Pritchett, Y. L., Ossanna, M. J., Swindle, R. W., Xu, J., & Detke, M. J. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815a4412 · Cited by 113 · cited 1×
“Given that about one-half of patients who initiate an antidepressant will fail to achieve remission (Thase et al., 2005; Machado et al., 2006; Thase et al., 2007), several treatment steps may be needed to achieve successful outcomes.”
BackgroundGopinath, S., Katon, W. J., Russo, J. E., & Ludman, E. J. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.10.023 · Cited by 111 · cited 1×
“Lack of adherence to antidepressant treatment is associated with poor treatment outcomes, including a greater risk of relapse (Gopinath et al., 2007), increased impairments in functioning (Burton et al., 2007), and greater risk of suicide (Ruengorn et al., 2012).”
BackgroundLobello, K. W., Preskorn, S. H., Guico-Pabia, C. J., Jiang, Q., Paul, J., Nichols, A. I., Patroneva, A., & Ninan, P. T. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04773blu · Cited by 109 · cited 1×
“…(extended release or immediate release), the cytochrome P450 (CYP) 2D6 poor metabolizer genotype is associated with significantly smaller mean improvements in depressive symptoms and significantly lower rates of remission vs those with the extensive metabolizer phenotype (Lobello et al., 2010).”
BackgroundZimmerman, M., Martinez, J. A., Attiullah, N., Friedman, M., Toba, C., Boerescu, D. A., & Rahgeb, M. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07203 · Cited by 108 · cited 1×
“Optimal treatment of depression should address all symptoms and functional impairment, minimize antidepressant side effects, address barriers to adherence, provide strategies for relapse prevention, and elevate patients’ overall sense of well-being and quality of life (Gelenberg et al.; Zimmerman et al., 2012; Kennedy…”
BackgroundDepression self-management support: A systematic review
Houle, J., Depatie, M. G., Bélanger-Dumontier, G., & Cardinal, C. (2013) · Patient Education and Counseling · doi:10.1016/j.pec.2013.01.012 · Cited by 106 · cited 1×
“, physical fitness, nutrition, weight loss, stress reduction/tolerability exercises, establishing a strong social network), may have long-term benefits, including mitigation of recurrence (Houle et al., 2013; Clarke et al., 2015; Lam et al., 2016).”
BackgroundJiang, W., Krishnan, R., Kuchibhatla, M., Cuffe, M. S., Martsberger, C., Arias, R. M., & O'Connor, C. M. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.10.013 · Cited by 106 · cited 1×
“This approach yields a more comprehensive MDD treatment plan and might also improve outcomes for comorbid conditions (Teh et al., 2010; Jiang et al., 2011).”
BackgroundReduced thalamic volumes in major depressive disorder
Nugent, A. C., Davis, R. M., Zarate, C. A., & Drevets, W. C. (2013) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2013.05.004 · Cited by 105 · cited 4×
“, 2016), and, notably, may reduce the burden of damage to brain areas (Arnone et al., 2013; Nugent et al., 2013).”
BackgroundResultInfluentialOrrell, C., Cohen, K., Mauff, K., Bangsberg, D. R., Maartens, G., & Wood, R. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000770 · Cited by 104 · cited 1×
“Tools for assisting the physician in monitoring adherence include electronic monitoring, pill counts, blister-packing medications, medication diaries, patient self-reporting, chart reviews, easy availability of prescription renewal, and pharmacy records (Osterberg and Blaschke, 2005; Velligan et al., 2006; Byerly et a…”
BackgroundDiet in the treatment of ADHD in children—A systematic review of the literature
Heilskov Rytter, M. J., Andersen, L. B. B., Houmann, T., Bilenberg, N., Hvolby, A., Mølgaard, C., Michaelsen, K. F., & Lauritzen, L. (2015) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2014.921933 · Cited by 103
Social and Occupational Functioning Assessment Scale (SOFAS)
Rybarczyk, B. D. (2010) · Springer eBooks · doi:10.1007/978-0-387-79948-3_428 · Cited by 102
Meta-analysis of relapse prevention antidepressant trials in depressive disorders
Glue, P., Donovan, M. R., Kolluri, S., & Emir, B. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048671003705441 · Cited by 100 · cited 1×
“Clinical evidence supports maintenance treatment of MDD with pharmacotherapy, psychotherapy, and other non-pharmacotherapies (Moller, 2008; Glue et al., 2010; Lam et al., 2016).”
BackgroundEfficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder
McIntyre, R. S., Florea, I., Tonnoir, B., Loft, H., Lam, R. W., & Christensen, M. C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m10744 · Cited by 100 · cited 1×
“Conversely, a higher level of functioning at baseline may be associated with better outcomes after treatment (McIntyre et al., 2017).”
BackgroundSelf-citationLam, R. W., Michalak, E. E., & Yatham, L. N. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-78 · Cited by 88
Social Functioning: Should it Become an Endpoint in Trials of Antidepressants?
Bech, P. (2005) · CNS Drugs · doi:10.2165/00023210-200519040-00004 · Cited by 88
A systematic review of duloxetine and venlafaxine in major depression, including unpublished data
Schueler, Y. ‐., Koesters, M., Wieseler, B., Grouven, U., Kromp, M., Kerekes, M. F., Kreis, J., Kaiser, T., Becker, T., & Weinmann, S. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01599.x · Cited by 87 · cited 1×
“While antidepressants may be similar in efficacy overall (Work Group on Major Depressive Disorder, 2010; Gartlehner et al., 2011; Schueler et al., 2011), published literature suggests there may be potential benefits of some drugs in individuals with specific symptoms or comorbid conditions…”
BackgroundFaurholt-Jepsen, M., Vinberg, M., Frost, M., Christensen, E. M., Bardram, J., & Kessing, L. V. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0309-5 · Cited by 87
Treatment Course With Antidepressant Therapy in Late-Life Depression
Sheline, Y. I., Disabato, B. M., Hranilovich, J., Morris, C., D’Angelo, G., Pieper, C., Toffanin, T., Taylor, W. D., MacFall, J. R., Wilkins, C., et al. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010122 · Cited by 86 · cited 2×
“, 2014) and was a significant predictor of poorer depression outcomes (Sheline et al., 2012) in patients with latelife depression.”
BackgroundPredictors of Self-Reported Antidepressant Adherence
Burra, T. A., Chen, E., McIntyre, R. S., Grace, S. L., Blackmore, E. R., & Stewart, D. E. (2007) · Behavioral Medicine · doi:10.3200/bmed.32.4.127-134 · Cited by 86 · cited 1×
“Obstacles to adherence include poor tolerability, social stigma, inadequate patient education, low motivation, medication cost, delayed onset of efficacy, weight gain, sexual dysfunction, failure of patients to perceive benefits of treatment, and premature discontinuation of treatment after symptoms have improved (Mas…”
BackgroundSelf-citationTreating to target in major depressive disorder: response to remission to functional recovery
McIntyre, R. S., Lee, Y., & Mansur, R. B. (2015) · CNS Spectrums · doi:10.1017/s1092852915000826 · Cited by 84 · cited 7×
“An undiagnosed medical or psychiatric comorbidity can interfere with response to MDD treatment (McIntyre et al., 2015; Bron et al., 2016).”
BackgroundInfluentialSelf-citationFunctional Recovery in Major Depressive Disorder: Focus on Early Optimized Treatment
Habert, J., Katzman, M. A., Oluboka, O. J., McIntyre, R. S., McIntosh, D., MacQueen, G. M., Khullar, A., Milev, R. V., Kjernisted, K. D., Chokka, P. R., et al. (2016) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.15r01926 · Cited by 84 · cited 9×
“An effective treatment plan adjusts to address these obstacles to optimize treatment as rapidly as possible (Culpepper et al., 2015; Habert et al., 2016).”
BackgroundInfluentialSelf-citationKatzman, M., & Sternat, T. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s111818 · Cited by 83 · cited 3×
“…may be similar in efficacy overall (Work Group on Major Depressive Disorder, 2010; Gartlehner et al., 2011; Schueler et al., 2011), published literature suggests there may be potential benefits of some drugs in individuals with specific symptoms or comorbid conditions (Sternat and Katzman, 2016).”
BackgroundInfluentialSelf-citationReasons for Antidepressant Nonadherence Among Veterans Treated in Primary Care Clinics
Fortney, J. C., Pyne, J. M., Edlund, M. J., Stecker, T., Mittal, D., Robinson, D. E., & Henderson, K. L. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05528blu · Cited by 80 · cited 1×
“Obstacles to adherence include poor tolerability, social stigma, inadequate patient education, low motivation, medication cost, delayed onset of efficacy, weight gain, sexual dysfunction, failure of patients to perceive benefits of treatment, and premature discontinuation of treatment after symptoms have improved (Mas…”
BackgroundOutcomes of 1014 naturalistically treated inpatients with major depressive episode
Seemüller, F., Riedel, M. J., Obermeier, M., Bauer, M., Adli, M., Kronmüller, K., Holsboer, F., Brieger, P., Laux, G., Bender, W., et al. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.11.011 · Cited by 79 · cited 1×
“…such as age at the onset of depression, time since the onset of depression, duration of the current episode, and the number of previous episodes may also predict treatment outcome (Warden et al., 2007; Howland et al., 2008; Fava et al., 2009; Seemuller et al., 2010; Joel et al., 2014).”
BackgroundDuric, V., & Duman, R. S. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1020-7 · Cited by 79 · cited 2×
“More recently, research has focused on whether antidepressant treatment can alter the course of brain deficits associated with MDD (Duric and Duman, 2013; Rotheneichner et al., 2014).”
BackgroundHippocampal Neurogenesis and Antidepressive Therapy: Shocking Relations
Rotheneichner, P., Lange, S., O’Sullivan, A., Marschallinger, J., Zaunmair, P., Geretsegger, C., Aigner, L., & Couillard-Despres, S. (2014) · Neural Plasticity · doi:10.1155/2014/723915 · Cited by 78 · cited 1×
“More recently, research has focused on whether antidepressant treatment can alter the course of brain deficits associated with MDD (Duric and Duman, 2013; Rotheneichner et al., 2014).”
BackgroundAdvances in Biomarkers of Major Depressive Disorder
Huang, T., & Lin, C.-C. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2014.11.003 · Cited by 77 · cited 1×
“Given that no biological markers have been established for depression (Huang and Lin, 2015), objective screening questionnaires are critical tools to employ when assessing a depressed patient.”
BackgroundCulpepper, L., Muskin, P. R., & Stahl, S. M. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.07.001 · Cited by 77 · cited 4×
“Additional steps to optimize patient adherence may involve patient education, setting realistic patient expectations, employing collaborative care systems, and providing adequate followup care (Cameron et al., 2014; Culpepper et al., 2015).”
BackgroundInfluentialPrevalence of ADHD symptoms across clinical stages of major depressive disorder
Bron, T. I., Bijlenga, D., Verduijn, J., Penninx, B. W. J. H., Beekman, A. T. F., & Kooij, J. J. S. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.02.053 · Cited by 77 · cited 1×
“An undiagnosed medical or psychiatric comorbidity can interfere with response to MDD treatment (McIntyre et al., 2015; Bron et al., 2016).”
BackgroundEffect of Depression Treatment on Chronic Pain Outcomes
Farmer Teh, C., Zaslavsky, A. M., Reynolds, C. F., & Cleary, P. D. (2010) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181c2a7a8 · Cited by 73 · cited 1×
“This approach yields a more comprehensive MDD treatment plan and might also improve outcomes for comorbid conditions (Teh et al., 2010; Jiang et al., 2011).”
BackgroundElbejjani, M., Fuhrer, R., Abrahamowicz, M., Mazoyer, B., Crivello, F., Tzourio, C., & Dufouil, C. (2015) · Psychological Medicine · doi:10.1017/s0033291714003055 · Cited by 73 · cited 2×
“, 2013) or at least a slowing of volume loss (Elbejjani et al., 2015), although this has not been observed in all studies (Schmaal et al.”
BackgroundResultBortolotto, V., Cuccurazzu, B., Canonico, P. L., & Grilli, M. (2014) · BioMed Research International · doi:10.1155/2014/612798 · Cited by 71 · cited 1×
“, 2015), and preclinical work (Duman and Aghajanian, 2012; Licznerski and Duman, 2013; Bortolotto et al., 2014) supports the hypothesis that depression may disrupt neural connections in mood-related circuits and provides preliminary evidence that treatment may ameliorate these processes.”
BackgroundDentate gyrus volume and memory performance in major depressive disorder
Travis, S., Coupland, N. J., Silversone, P. H., Huang, Y., Fujiwara, E., Carter, R., Seres, P., & Malykhin, N. V. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.09.048 · Cited by 71
Sutton, S., Kinmonth, A.-L., Hardeman, W., Hughes, D., Boase, S., Prevost, A. T., Kellar, I., Graffy, J., Griffin, S., & Farmer, A. (2014) · Annals of Behavioral Medicine · doi:10.1007/s12160-014-9595-x · Cited by 70
Furtado, C. P., Hoy, K. E., Maller, J. J., Savage, G., Daskalakis, Z. J., & Fitzgerald, P. B. (2013) · Brain Stimulation · doi:10.1016/j.brs.2012.06.006 · Cited by 67 · cited 2×
“…depressive symptoms may promote chronic neuronal loss and suppress neurogenesis in the hippocampus (Boldrini et al., 2012, 2013; Duric et al., 2013; Furtado et al., 2013; Phillips et al., 2015), and preclinical work (Duman and Aghajanian, 2012; Licznerski and Duman, 2013; Bortolotto et al.,…”
BackgroundIs duration of illness really influencing outcome in major psychoses?
Altamura, A. C., Serati, M., & Buoli, M. (2015) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2014.990919 · Cited by 67 · cited 1×
“Additionally, the duration of untreated illness is a significant predictor of response, remission, and time to remission (Gormley et al., 1999; Okuda et al., 2010; Bukh et al., 2013; Altamura et al., 2015).”
BackgroundThe association of antidepressant medication adherence with employee disability absences.
Burton, W. N., Chen, C., Conti, D. J., Schultz, A. B., & Edington, D. W. (2007) · PubMed · Cited by 65
Howland, R. H., Wilson, M. G., Kornstein, S. G., Clayton, A. H., Trivedi, M. H., Wohlreich, M. M., & Fava, M. (2008) · Annals of Clinical Psychiatry · doi:10.1080/10401230802437639 · Cited by 62 · cited 1×
“…such as age at the onset of depression, time since the onset of depression, duration of the current episode, and the number of previous episodes may also predict treatment outcome (Warden et al., 2007; Howland et al., 2008; Fava et al., 2009; Seemuller et al., 2010; Joel et al., 2014).”
BackgroundGartlehner, G., Hansen, R. A., Carey, T. S., Lohr, K. N., Gaynes, B. N., & Randolph, L. C. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200503000-00001 · Cited by 60 · cited 1×
“Efficacy and tolerability differences between drugs must be balanced based on the needs of the individual patient (Gartlehner et al., 2005; Machado et al., 2006; Gartlehner et al., 2008a, 2008b; Cipriani et al., 2009).”
BackgroundOptimizing the management of depression: primary care experience
Cameron, C., Habert, J., Anand, L., & Furtado, M. (2014) · Psychiatry Research · doi:10.1016/s0165-1781(14)70005-8 · Cited by 59 · cited 4×
“Additional steps to optimize patient adherence may involve patient education, setting realistic patient expectations, employing collaborative care systems, and providing adequate followup care (Cameron et al., 2014; Culpepper et al., 2015).”
BackgroundInfluentialSelf-citationSafety and efficacy of generic drugs with respect to brand formulation
Gallelli, L., Palleria, C., Vuono, A. D., Mumoli, L., Vasapollo, P., Piro, B., & Russo, E. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.120972 · Cited by 59 · cited 1×
“, 2012), there nonetheless may be efficacy or tolerability differences for some patients taking generic drugs, possibly related to difference in excipients (Gallelli et al., 2013; Andrade, 2015).”
BackgroundThase, M. E. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/mthase · Cited by 57 · cited 2×
“…have yet to demonstrate a positive impact on health outcomes in clinical practice; however, future research may eventually prove biomarkers to be beneficial in selecting appropriate antidepressants in specific patient populations (Dunlop and Mayberg, 2014; Leuchter et al., 2014; Thase, 2014a).”
BackgroundMethodDynamic Prediction of Treatment Response in Late-Life Depression
Joel, I., Begley, A. E., Mulsant, B. H., Lenze, E. J., Mazumdar, S., Dew, M. A., Blumberger, D., Butters, M., & Reynolds, C. F. (2014) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2012.07.002 · Cited by 55 · cited 1×
“…such as age at the onset of depression, time since the onset of depression, duration of the current episode, and the number of previous episodes may also predict treatment outcome (Warden et al., 2007; Howland et al., 2008; Fava et al., 2009; Seemuller et al., 2010; Joel et al., 2014).”
BackgroundDuration of untreated illness and antidepressant fluvoxamine response in major depressive disorder
Okuda, A., Suzuki, T., Kishi, T., Yamanouchi, Y., Umeda, K., Haitoh, H., Hashimoto, S., Ozaki, N., & Iwata, N. (2010) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2010.02091.x · Cited by 54 · cited 2×
“Furthermore, delaying effective treatment may reduce the likelihood of both asymptomatic remission and functional recovery, and increase the time to achieve remission (Gormley et al., 1999; Okuda et al., 2010; Bukh et al., 2013; Ghio et al., 2014).”
BackgroundGeerlings, M. I., Brickman, A. M., Schupf, N., Devanand, D. P., Luchsinger, J. A., Mayeux, R., & Small, S. A. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-112009 · Cited by 52 · cited 1×
“…in brain morphometry and circuit dysfunction that can be observed as volume loss in the hippocampus and other areas implicated in depression (Geerlings et al., 2012; Sheline et al., 2012; Arnone et al., 2013; Huang et al., 2013; Nugent et al., 2013; Zhao et al., 2014; Schmaal et al.,…”
BackgroundState dependent posterior hippocampal volume increases in patients with major depressive disorder
Schermuly, I., Wolf, D. G. F., Lieb, K., Stoeter, P., & Fellgiebel, A. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.07.017 · Cited by 52
Gormley, N. A., O’Leary, D., & Costello, F. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00133-5 · Cited by 48 · cited 2×
“Furthermore, delaying effective treatment may reduce the likelihood of both asymptomatic remission and functional recovery, and increase the time to achieve remission (Gormley et al., 1999; Okuda et al., 2010; Bukh et al., 2013; Ghio et al., 2014).”
BackgroundWithdrawal of Generic Budeprion for Nonbioequivalence
Woodcock, J., Khan, M. A., & Yu, L. X. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1212969 · Cited by 48 · cited 1×
“However, even though approval of a generic medication requires a demonstration of bioequivalence, which does sometimes fail (Chenu et al., 2009; Woodcock et al., 2012), there nonetheless may be efficacy or tolerability differences for some patients taking generic drugs, possibly related to difference in excipients (Ga…”
BackgroundFactors related to suicide attempts among individuals with major depressive disorder
Patumanond, J., Ruengorn, C., Sanichwankul, Niwatananum, Mahatnirunkul, & Pumpaisalchai (2012) · International Journal of General Medicine · doi:10.2147/ijgm.s30874 · Cited by 47 · cited 1×
“Lack of adherence to antidepressant treatment is associated with poor treatment outcomes, including a greater risk of relapse (Gopinath et al., 2007), increased impairments in functioning (Burton et al., 2007), and greater risk of suicide (Ruengorn et al., 2012).”
BackgroundWernli, K. J., Henrikson, N. B., Morrison, C. C., Nguyen, M. T., Pocobelli, G. S., & Whitlock, E. P. (2016) · Europe PMC (PubMed Central) · Cited by 46
Nakonezny, P. A., Byerly, M., & Rush, A. J. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2007.05.001 · Cited by 45 · cited 1×
“Tools for assisting the physician in monitoring adherence include electronic monitoring, pill counts, blister-packing medications, medication diaries, patient self-reporting, chart reviews, easy availability of prescription renewal, and pharmacy records (Osterberg and Blaschke, 2005; Velligan et al., 2006; Byerly et a…”
BackgroundProbst-Schendzielorz, K., Viviani, R., & Stingl, J. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1052791 · Cited by 42 · cited 1×
“These findings suggest that certain patients may require therapeutic drug monitoring and/or dose adjustment for efficacy or safety if antidepressant drugs whose exposure or efficacy vary with metabolizer genotype are prescribed (Probst-Schendzielorz et al., 2015; Zhang et al., 2015).”
BackgroundScreening for depression: a systematic review and meta-analysis
Keshavarz, H., Fitzpatrick-Lewis, D., Streiner, D. L., Maureen, R., Ali, U., Shannon, H. S., & Raina, P. (2013) · CMAJ Open · doi:10.9778/cmajo.20130030 · Cited by 42 · cited 1×
“Concerns with screening all adult patients include the lack of robust evidence supporting routine screening (due to the paucity of available data on its benefits and harms), the high likelihood that patients who screen positive will have been previously identified as suffering from depression, and the risk of identify…”
BackgroundIntermediate phenotypes and biomarkers of treatment outcome in major depressive disorder
Leuchter, A. F., Hunter, A. M., Krantz, D. E., & Cook, I. A. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/aleuchter · Cited by 41 · cited 1×
“To date, pharmacogenetics/genomic biomarkers have yet to demonstrate a positive impact on health outcomes in clinical practice; however, future research may eventually prove biomarkers to be beneficial in selecting appropriate antidepressants in specific patient populations (Dunlop and Mayberg, 2014; Leuchter et al.,…”
BackgroundThe US Food and Drug Administration’s Perspective on the New Antidepressant Vortioxetine
Zhang, J., Mathis, M. V., Sellers, J. W., Kordzakhia, G., Jackson, A. J., Dow, A. L., Yang, P., Fossom, L. H., Zhu, H., Patel, H., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14r09164 · Cited by 41 · cited 2×
“These findings suggest that certain patients may require therapeutic drug monitoring and/or dose adjustment for efficacy or safety if antidepressant drugs whose exposure or efficacy vary with metabolizer genotype are prescribed (Probst-Schendzielorz et al., 2015; Zhang et al., 2015).”
BackgroundPredicting Response to Fluoxetine in Geriatric Patients With Major Depression
Koran, L. M., Hamilton, S. H., Hertzman, M., Meyers, B. S., Halaris, A. E., Tollefson, G. D., Downs, J. M., Folks, D. G., Jeste, D. V., Lazarus, L. W., et al. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199512000-00006 · Cited by 38
Diagnosis delay in first episodes of major depression: A study of primary care patients in Spain
Huerta-Ramírez, R., Bertsch, J., Cabello, M., Roca, M., Haro, J. M., & Ayuso‐Mateos, J. L. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.009 · Cited by 38
Major depressive disorder: psychosocial impairment and key considerations in functional improvement.
Papakostas, G. I. (2009) · PubMed · Cited by 37
Chenu, F., Batten, L. A., Zernig, G., Ladstaetter, E., Hébert, C., & Blier, P. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05315 · Cited by 32
Self-citationMohr, D., Montague, E., Stiles-Shields, C., Kaiser, S., Brenner, C., Palac, H., Carty-Fickes, E., & Duffecy, J. (2015) · EAI Endorsed Transactions on Pervasive Health and Technology · doi:10.4108/icst.pervasivehealth.2015.259042 · Cited by 32 · cited 4×
“One such tool is MoodFx, an interactive website focusing on depression and anxiety (Work With Us Program, 2014; Mohr et al., 2015; MoodFX website, 2016).”
BackgroundMethodInfluentialEarly Prediction of Fluoxetine Response for Han Chinese Inpatients With Major Depressive Disorder
Lin, C., Lane, H., Chen, C., Juo, S. H., & Yen, C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318210856f · Cited by 32
van Onzenoort, H. A. W., Neef, C., Verberk, W. J., van Iperen, H. P., de Leeuw, P. W., & van der Kuy, P. H. M. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100592 · Cited by 29
A Review of Pharmacologic Strategies for Switching to Atypical Antipsychotics
Masand, P. S. (2005) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v07n0309 · Cited by 28
Lam, R. W., Endicott, J., Hsu, M.-A., Fayyad, R., Guico-Pabia, C., & Boucher, M. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000031 · Cited by 28
Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder
Fava, M., Wiltse, C. G., Walker, D. J., Brecht, S., Chen, A., & David, P. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.05.023 · Cited by 27 · cited 1×
“…such as age at the onset of depression, time since the onset of depression, duration of the current episode, and the number of previous episodes may also predict treatment outcome (Warden et al., 2007; Howland et al., 2008; Fava et al., 2009; Seemuller et al., 2010; Joel et al., 2014).”
BackgroundManaging Medical Comorbidities in Patients With Depression to Improve Prognosis
Thase, M. E. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14077su1c.04 · Cited by 26 · cited 2×
“Depression symptoms may be missed in patients presenting with symptoms of comorbid conditions, resulting in delayed diagnosis and treatment (McGuire et al., 2014; Lam et al., 2016; Thase, 2016).”
BackgroundBioequivalence of Generic Drugs
Andrade, C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15f10300 · Cited by 24 · cited 2×
“…a demonstration of bioequivalence, which does sometimes fail (Chenu et al., 2009; Woodcock et al., 2012), there nonetheless may be efficacy or tolerability differences for some patients taking generic drugs, possibly related to difference in excipients (Gallelli et al., 2013; Andrade, 2015).”
BackgroundRomera, I., Pérez, V., Menchón, J. M., Schacht, A., Papen, R., Neuhauser, D., Abbar, M., Picard, H., & Gilaberte, I. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.05.024 · Cited by 24 · cited 1×
“Providing a longer treatment trial (8 weeks vs 4 weeks) before switching is associated with poorer functional outcomes, even among patients who remit on the second treatment (Romera et al., 2012).”
BackgroundSoares, C. N., Fayyad, R. S., & Guico‐Pabia, C. J. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000049 · Cited by 24
Epstein, I., Szpindel, I., & Katzman, M. A. (2014) · Psychiatry Research · doi:10.1016/s0165-1781(14)70003-4 · Cited by 23 · cited 1×
“…be associated with a higher risk of MDD (e.g., substance abuse, low hedonic tone, or attention deficit hyperactivity disorder [ADHD]; Kessler et al., 2003; Sternat et al., 2014), they are better able to remain alert for signs of depression in patients with those conditions (Epstein et al., 2014).”
BackgroundSelf-citationHusarova, V. M., Bittšanský, M., Ondrejka, I., Kerna, V., & Dobrota, D. (2012) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2011.07.006 · Cited by 23
Identifying Patients With Depression Who Require a Change in Treatment and Implementing That Change
Papakostas, G. I. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14077su1c.03 · Cited by 23 · cited 1×
“Once an initial antidepressant selection is made, physicians should be thorough and persistent in monitoring patient response through clinical interviews and by using validated measurement tools (Papakostas, 2016).”
Soares, C. N., Endicott, J., Boucher, M., Fayyad, R. S., & Guico-Pabia, C. J. (2014) · CNS Spectrums · doi:10.1017/s1092852914000066 · Cited by 22
Manolopoulos, V. G., Ragia, G., & Alevizopoulos, G. A. (2012) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2011-0033 · Cited by 21 · cited 1×
“Tolerability concerns are heightened for patients who have comorbid conditions that could be worsened by antidepressant effects, or who take concomitant medications likely to contribute to drug-drug interactions (Manolopoulos et al., 2012; Kennedy et al., 2016; Thase et al., 2016).”
BackgroundMcGuire, A., Eastwood, J., Hays, R. D., Macabasco‐O’Connell, A., & Doering, L. V. (2014) · American Journal of Critical Care · doi:10.4037/ajcc2014146 · Cited by 17 · cited 3×
“It is essential to consider that a patient’s concept of wellness may differ substantially from that of the treating physician (Zimmerman et al., 2006; McIntyre et al., 2015), and ultimately, it is the patient’s concept that is the most important treatment goal.”
BackgroundEarly response as predictor of final remission in elderly depressed patients
Kok, R., van Baarsen, C., Nolen, W. A., & Heeren, T. J. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2261 · Cited by 15
Functional outcomes in MDD: established and emerging assessment tools.
Endicott, J., & Dorries, K. M. (2009) · PubMed · Cited by 15
Thase, M. E., Gommoll, C., Chen, C., Kramer, K. L., & Sambunaris, A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000138 · Cited by 15
Adherence to guidelines and effectiveness of inpatient treatment for unipolar depression
Köhler, S., Hoffmann, S., Unger, T., Steinacher, B., & Fydrich, T. (2011) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2011.638142 · Cited by 14 · cited 1×
“Medication adherence is critical to achieving full, functional recovery and is one of the major challenges hindering optimal treatment of MDD (Kohler et al., 2012; Ho et al., 2015; Lam et al., 2016).”
BackgroundShort-term escitalopram treatment and hippocampal volume
Godlewska, B. R., Hasselmann, H., Igoumenou, A., Norbury, R., & Cowen, P. J. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3771-3 · Cited by 11
Hedonic Tone: A Bridge between the Psychobiology of Depression and its Comorbidities
A, S. T. L. (2014) · Journal of Depression & Anxiety · doi:10.4172/2167-1044.1000147 · Cited by 6
Translating Clinical Science Into Effective Therapies
Thase, M. E. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13048tx1c · Cited by 3 · cited 2×
“…have yet to demonstrate a positive impact on health outcomes in clinical practice; however, future research may eventually prove biomarkers to be beneficial in selecting appropriate antidepressants in specific patient populations (Dunlop and Mayberg, 2014; Leuchter et al., 2014; Thase, 2014a).”
BackgroundMethodManagement of Newer Antidepressant Medications in U.S. Commercial Health Plans.
Hodgkin, D., Horgan, C. M., Creedon, T. B., Merrick, E. L., & Stewart, M. T. (2015) · PubMed · Cited by 2
Research works printed but not linked: 5
- American Psychiatric Association, 2013, Major depressive disorder, 160
- Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA), 2011, Canadian ADHD Practice Guidelines
- Canadian Network for Mood and AnxietyTreatments, 2017, SwitchRx: switching antipsychotic medications
- Sheehan, 2000, Sheehan Disability Scale, 113
- Work Group on Major Depressive Disorder. Practice Guideline For the Treatment of Patients With Major Depressive Disorder, edition 3. American Psychiatric Association, 2010
Cited by
Sajjadian, M., Lam, R. W. M., Milev, R. V., Rotzinger, S., Frey, B. N., Soares, C. N., Parikh, S. V., Foster, J. A., Turecki, G., Müller, D. J., et al. (2021) · Psychological Medicine · doi:10.1017/s0033291721003871 · Cited by 180
“If we could predict response to a specific treatment from individual characteristics, we could reduce the duration of depression and improve long-term functional outcomes (Oluboka et al., 2018).”
BackgroundSelf-citationKasper, S., Cubała, W. J., Fagiolini, A., Ramos-Quiroga, J. A., Souery, D., & Young, A. H. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1836399 · Cited by 85
Improving Depression Outcome by Patient-Centered Medical Management
Rush, A. J., & Thase, M. E. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18040398 · Cited by 76
New trends in personalized treatment of depression
Sampogna, G., Toni, C., Catapano, P., Rocca, B. D., Vincenzo, M. D., Luciano, M., & Fiorillo, A. (2023) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000903 · Cited by 88
“The definition of functional recovery includes a condition in which the patient starts to enjoy again his/her usual activities, returns to work and is able to take care of him/herself [10].”
BackgroundHogg, B., Medina, J. C., Gardoki-Souto, I., Serbanescu, I., Moreno‐Alcázar, A., Pashoja, A. C., Coppens, E., Tóth, M. D., Fanaj, N., Greiner, B. A., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.04.071 · Cited by 80
“Prevention, early recognition and treatment of anxiety and depressive disorders are crucial aspects in improving prognosis (Craske and Stein, 2016; Kraus et al., 2019; Olobuka et al., 2018).”
Background
Metadata
- Authors
- Oluboka, O. J., Katzman, M. A., Habert, J., McIntosh, D., MacQueen, G. M., Milev, R. V., McIntyre, R. S., & Blier, P.
- Affiliations
- University of Calgary (CA)
- START Clinic (CA)
- University of Toronto (CA)
- University of British Columbia (CA)
- Queen's University (CA)
- University of Ottawa (CA)
- Corresponding author
- Oluboka, Oloruntoba J
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-09-08
- Volume
- 21
- Issue
- 2
- Pages
- 128-144
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC5793729
- OpenAlex
- W2753506619
- Cited by
- 104
- References
- 167
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 3 · 2023: 8 · 2022: 27 · 2021: 14 · 2020: 11 · 2019: 12 · 2018: 5
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Pfizer Canada
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, functional recovery, early treatment, pharmacotherapy, measurement-based care, personalized treatment, patient-centered care, treatment delay, brain morphometry, comorbidities, patient preferences
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Humans, Patient-Centered Care, Patient Preference, Early Medical Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
